U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 3368

1.
Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews
Qiyuan Zhao, Jiantong Shen, Jingya Lu, Qi Jiang, Yuanyuan Wang
BMC Cardiovasc Disord. 2020; 20: 179. Published online 2020 Apr 17. doi: 10.1186/s12872-020-01442-z
PMCID:
PMC7164287
ArticlePDF–721K
2.
Aliskiren increases aquaporin-2 expression and attenuates lithium-induced nephrogenic diabetes insipidus
Yu Lin, Tiezheng Zhang, Pinning Feng, Miaojuan Qiu, Qiaojuan Liu, Suchun Li, Peili Zheng, Yonglun Kong, Moshe Levi, Chunling Li, Weidong Wang
Am J Physiol Renal Physiol. 2017 Oct 1; 313(4): F914–F925. Published online 2017 Feb 22. doi: 10.1152/ajprenal.00553.2016
PMCID:
PMC6148297
Article
3.
Blood pressure lowering efficacy of renin inhibitors for primary hypertension
Vijaya M Musini, Kendra AK Lawrence, Patricia M Fortin, Ken Bassett, James M Wright, Cochrane Hypertension Group
Cochrane Database Syst Rev. 2017 Apr; 2017(4): CD007066. Published online 2017 Apr 5. doi: 10.1002/14651858.CD007066.pub3
PMCID:
PMC6478238
ArticlePDF–965K
4.
Combination of Chymostatin and Aliskiren attenuates ER stress induced by lipid overload in kidney tubular cells
Miaojuan Qiu, Suchun Li, Lizi Jin, Pinning Feng, Yonglun Kong, Xiaoduo Zhao, Yu Lin, Yunyun Xu, Chunling Li, Weidong Wang
Lipids Health Dis. 2018; 17: 183. Published online 2018 Jul 31. doi: 10.1186/s12944-018-0818-1
PMCID:
PMC6069859
ArticlePDF–1.9M
5.
Aliskiren Reduces Hepatic steatosis and Epididymal Fat Mass and Increases Skeletal Muscle Insulin Sensitivity in High-Fat Diet-Fed Mice
Kuei-Chuan Lee, Yun-Cheng Hsieh, Ying-Ying Yang, Che-Chang Chan, Yi-Hsiang Huang, Han-Chieh Lin
Sci Rep. 2016; 6: 18899. Published online 2016 Jan 6. doi: 10.1038/srep18899
PMCID:
PMC4702081
ArticlePDF–1.8M
6.
The Anti-Inflammatory Effect of Different Doses of Aliskiren in Rat Models of Inflammation
Tavga Ahmed Aziz, Ahmed Azad Kareem, Hemn Hassan Othman, Zheen Aorahman Ahmed
Drug Des Devel Ther. 2020; 14: 2841–2851. Published online 2020 Jul 20. doi: 10.2147/DDDT.S255607
PMCID:
PMC7381093
ArticlePDF–4.8M
7.
Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients
Sean L Zheng, Alistair J Roddick, Salma Ayis
Diab Vasc Dis Res. 2017 Sep; 14(5): 400–406. Published online 2017 Aug 27. doi: 10.1177/1479164117715854
PMCID:
PMC5600262
ArticlePDF–873K
8.
Angioedemas associated with renin-angiotensin system blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports
Diana Dubrall, Matthias Schmid, Julia Carolin Stingl, Bernhardt Sachs
PLoS One. 2020; 15(3): e0230632. Published online 2020 Mar 26. doi: 10.1371/journal.pone.0230632
PMCID:
PMC7098604
ArticlePDF–3.6M
9.
Effects of Aliskiren Monotherapy versus Amlodipine Monotherapy in Hypertensive Patients with Obesity or Type 2 Diabetes Mellitus
Yasufumi Seki, Satoshi Morimoto, Shihori Kimura, Noriyoshi Takano, Kaoru Yamashita, Kanako Bokuda, Nobukazu Sasaki, Daisuke Watanabe, Atsuhiro Ichihara
Kidney Blood Press Res. 2023 Jan-Dec; 48(1): 688–700. Published online 2023 Oct 20. doi: 10.1159/000533834
PMCID:
PMC10652658
Article
10.
Protective Effects of Nanoparticle-Loaded Aliskiren on Cardiovascular System in Spontaneously Hypertensive Rats
Olga Pechanova, Andrej Barta, Martina Koneracka, Vlasta Zavisova, Martina Kubovcikova, Jana Klimentova, Jozef Tӧrӧk, Anna Zemancikova, Martina Cebova
Molecules. 2019 Aug; 24(15): 2710. Published online 2019 Jul 25. doi: 10.3390/molecules24152710
PMCID:
PMC6695910
ArticlePDF–4.5M
11.
Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry
Iris Kistner, Uwe Zeymer, Ralf Dechend, Ina Hagedorn, Thomas Riemer, Peter Bramlage, David Pittrow, Jochen Senges, Roland E. Schmieder
J Clin Hypertens (Greenwich) 2016 Oct; 18(10): 1045–1053. Published online 2016 Apr 20. doi: 10.1111/jch.12828
PMCID:
PMC8031948
ArticlePDF–182K
12.
Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin
Sungjin Chung, Soojeong Kim, Minyoung Kim, Eun Sil Koh, Seok Joon Shin, Cheol Whee Park, Yoon Sik Chang, Ho-Shik Kim
PLoS One. 2017; 12(7): e0181757. Published online 2017 Jul 28. doi: 10.1371/journal.pone.0181757
Correction in:
PLoS One. 2018; 13(5): e0196885.
PMCID:
PMC5533315
ArticlePDF–11M
13.
Utilisation and Tolerability of Aliskiren in the Primary Care Setting in England
Abigail L. Coughtrie, Claire Doe, Deborah Layton, Saad A. W. Shakir
J Clin Hypertens (Greenwich) 2016 Dec; 18(12): 1237–1243. Published online 2016 Jun 3. doi: 10.1111/jch.12852
PMCID:
PMC8031493
ArticlePDF–94K
14.
Long-term effects of a renin inhibitor versus a thiazide diuretic on arterial stiffness and left ventricular diastolic function in elderly hypertensive patients
Yoshiyuki Okada, Shigeki Shibata, Naoki Fujimoto, Stuart A. Best, Benjamin D. Levine, Qi Fu
Am J Physiol Regul Integr Comp Physiol. 2017 Oct 1; 313(4): R400–R409. Published online 2017 Jul 19. doi: 10.1152/ajpregu.00125.2017
PMCID:
PMC5668614
Article
15.
Aliskiren has chondroprotective efficacy in a rat model of osteoarthritis through suppression of the local renin-angiotensin system
Kaizhong Yan, Yixin Shen
Mol Med Rep. 2017 Oct; 16(4): 3965–3973. Published online 2017 Jul 28. doi: 10.3892/mmr.2017.7110
PMCID:
PMC5646976
ArticlePDF–1.9M
16.
Renin inhibition improves metabolic syndrome, and reduces angiotensin II levels and oxidative stress in visceral fat tissues in fructose-fed rats
Chu-Lin Chou, Heng Lin, Jin-Shuen Chen, Te-Chao Fang
PLoS One. 2017; 12(7): e0180712. Published online 2017 Jul 10. doi: 10.1371/journal.pone.0180712
PMCID:
PMC5507254
ArticlePDF–6.4M
17.
Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy
Kalathil K Sureshkumar
Vasc Health Risk Manag. 2008 Dec; 4(6): 1205–1220. doi: 10.2147/vhrm.s3364
PMCID:
PMC2663460
ArticlePDF–183K
18.
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Eduardo Pimenta, Suzanne Oparil
Vasc Health Risk Manag. 2009; 5: 453–463. Published online 2009 May 21. doi: 10.2147/vhrm.s4291
PMCID:
PMC2686262
ArticlePDF–377K
19.
Aliskiren and Amlodipine in the Management of Essential Hypertension: Meta-Analysis of Randomized Controlled Trials
Yukai Liu, Ken Chen, Xun Kou, Yu Han, Lin Zhou, Chunyu Zeng
PLoS One. 2013; 8(7): e70111. Published online 2013 Jul 29. doi: 10.1371/journal.pone.0070111
PMCID:
PMC3726495
ArticlePDF–1.8M
20.
Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects
Sujata Vaidyanathan, Joanne Jermany, ChingMing Yeh, Marie-Noelle Bizot, Riccardo Camisasca
Br J Clin Pharmacol. 2006 Dec; 62(6): 690–698. doi: 10.1111/j.1365-2125.2006.02696.x
PMCID:
PMC1885182
ArticlePDF–193K

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Search details

See more...

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center